Cargando…
Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) represents about 85% of the reported cases of lung cancer. Acquired resistance to targeted therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, is not uncommon. It is thus vital to explore novel strategies to rest...
Autores principales: | Sin, Thomas K., Wang, Fengfeng, Meng, Fei, Wong, S. C. Cesar, Cho, William C. S., Siu, Parco M., Chan, Lawrence W. C., Yung, Benjamin Y. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783968/ https://www.ncbi.nlm.nih.gov/pubmed/26891293 http://dx.doi.org/10.3390/ijms17020237 |
Ejemplares similares
-
Circulating Plasma MicroRNAs As Diagnostic Markers for NSCLC
por: Hou, Jinpao, et al.
Publicado: (2016) -
Combination therapy of gefitinib and miR-30a-5p may overcome acquired
drug resistance through regulating the PI3K/AKT pathway in non-small cell lung
cancer
por: Wang, Fengfeng, et al.
Publicado: (2020) -
Gene Network Exploration of Crosstalk between Apoptosis and Autophagy in Chronic Myelogenous Leukemia
por: Wang, Fengfeng, et al.
Publicado: (2015) -
Coexpression Pattern Analysis of NPM1-Associated Genes in Chronic Myelogenous Leukemia
por: Wang, Fengfeng, et al.
Publicado: (2015) -
Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer
por: Wang, Y, et al.
Publicado: (2014)